Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | LIPE | Q05469 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24755009 | 0.82 | LIPE (0.35) | HDAC3HDAC1HDAC2HDAC6MMP2 | |
| SCHEMBL29806705 | 0.82 | LIPE (0.35) | HDAC3HDAC1HDAC2HDAC6MMP2 | |
| SCHEMBL22932341 | 0.81 | XDH (0.33) | LIPE | |
| SCHEMBL24755070 | 0.76 | NQO2 (0.35) | — | |
| SCHEMBL29806167 | 0.76 | RXRA (0.33) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL22931782 | 0.76 | RXRA (0.33) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL22932338 | 0.74 | CNR1 (0.32) | HDAC1HDAC6 | |
| SCHEMBL22931775 | 0.69 | RXRA (0.32) | HDAC3HDAC1HDAC2HDAC6MMP2 | |
| SCHEMBL29420832 | 0.69 | RXRA (0.32) | HDAC3HDAC1HDAC2HDAC6MMP2 | |
| SCHEMBL22932337 | 0.68 | JAK3 (0.41) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | HDAC3 746/4885HDAC1 882/4885HDAC2 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.